Temelimab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Temelimab (also known as GNbAC1[1]) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.[2][3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions.[1] As of 2023, it is also being studied for cognitive impairment in long COVID.[4]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
